PetMed Express, Inc.
|$872 M||Market Cap|
|5.7%||EBIT / EV|
|4.4%||FCF / EV|
|2.3%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|The EBIT / Enterprise Value of 5.7% ranks as Average.|
|The Free Cash Flow / Enterprise Value of 4.4% ranks as Average.|
|The Return on Invested Capital Value of 123.8% ranks as Very High.|
|The Cash Return on Capital Value of 96.0% ranks as Very High.|
|The 3 Year Average Revenue Growth Value of 2.3% ranks as Average.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 4.91.|
PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins and nutritional supplements, and hygiene products; and it also offers prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, antibiotics and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail/print advertising campaigns. The company's products include a majority of brands of medication such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution and Rimadyl. Petmed Express was founded in January 1996 and is headquartered in Pompano Beach, FL.
|Cognex Corporation (CGNX)|
|iRobot Corporation (IRBT)|
|Target Corporation (TGT)|
|Buckle, Inc. (BKE)|
|Talend SA Sponsored ADR (TLND)|